Background Since long-term administrations of anti-hyperlipidemic agents result in reduction in % stenosis or increase in minimum lumen diameter (MLD) of stenotic coronary segments, it is generally believed that anti-hyperlipidemic agents stabilize vulnerable coronary plaques. However, recent pathologic and angioscopic studies revealed that vulnerability of coronary plaques is not related to severity of stenosis and the rims rather than top of the plaques disrupt, and therefore, angiography is not adequate for evaluation of vulnerability.
INTRODUCTION
Since long-term administrations of anti-hyperlipidemic agents result in reduction of cardiac events and increases survival rate, it is generally believed that anti-hyperlipidemic agents stabilize vulneable coronary plaques, however without definite evidence [1] [2] [3] . Coronary angiographic follow-up studies also demonstrated that their beneficial effects are not necessarily accompanied by significant reduction in severity of coronary stenoses [4] [5] [6] [7] .
Recent pathologic and angioscopic studies revealed that vulneability of coronary plaques is not related to severity of stenoses and the rims rather than top of the plaques disrupt [8, 9] . Also, angioscopic studies in acute coronary syndromes demonstrated that plaques in less stenotic portions disrupt in a certain group of patients [10] . Therefore, angiography is not adequate for evaluation of vulnerability.
Angioscopy enables macroscopic pathological evaluation of the coronary plaques. Therefore, we carried out a prospective angioscopic open trial for evaluation of the stabilizing effects of bezafibrate on coronary plaques in patients who underwent coronary angioplasty.
SUBJECTS AND METHODS

Angioscopes and their Manipulation
Angioscopes used in this study were 4.7F in external diameter with an inflatable balloon at the most tip (Clinical Supply Co, Gifu, Japan). A fiberscope (image guide 3000 or 6000 pixels and light guide 200 pixels) was included in a guiding catheter.
For observation, balloon was inflated with carbon dioxide and body temperature heparinized (10 U/ ml) saline was infused manually or when necessary by a power injector at a rate of 2-3 ml/sec. The fiberscope can be advanced over a 0.014 inch guide wire for up to 5 cm while the guiding catheter was fixed. Therefore, coronary luminal changes can be observed successibly for considerable length during single observation (Fig. 1 [11, 12, 13] . Also, they are classified into regular (non-disrupted) and complex (disrupted) plaques [13, 14] . Our angioscopic and pathologic studies revealed that glistening yellow plaques are vulneable and yellow one the next. Our prospective angioscopic follow-up study also confirmed that glistening yellow plaques are vulnerable [10] .
Therefore, the vulnerability score of plaques was determined based on their color and surface morphology and it was compared before and 6 months later (Table I) .
Angiographic Measurement
Percentage stenoses were calibrated using cineangiograms and were compared before and 6 months later. An increase of 25% and a decrease of 25% in % stenoses were determined as progression and regression, respectively, and they were compared between the control and bezafibrate groups. No significant differences were observed in patient's background between the control and bezafibrate groups (Table II) . Figure 2 shows representative examples of the changes in coronary plaques in the treated group. In Fig. 2A , a glistening yellow complex (rough surfaced) plaque before was changed into non-glistening yellow regular plaque (vulnerability score from 4 to 2). In Fig. 2B , a non-glistening yellow regular plaque disappeared almost completely and the luminal surface became white (vulnerability score from 2 to 0). In Fig. 2C In bezafibrate group, % stenosis assessed by angiography was decreased. However, no significant differences were observed in progression or regression assessed by angiography between the two groups (Fig. 4) .
Two or more plaques with vulnerability score of or more were observed in 4 patients treated.
In 2 of these patients, vulnerability score was decreased in one plaque but was unchanged in others (Fig. 5) . 
Changes in Plasma Lipids
The value of T Chol was unchanged and that of TG was decreased. On the contrary, the value of HDL was increased in bezafibrate group but were unchanged in control group (Fig. 6 ). In bezafibrate group, both T Chol and TG were decreased and HDL was increased in patients with reduced vulnerability score but were unchanged in those with unchanged score (Fig. 7) . [11, 12] .
In this study, a glistening yellow plaque was changed into non-glistening yellow plaques after 6 month's administration of bezafibrate. Although fibrotic responses to the mechanical damages induced by guide wire passing over the plaque during observation can not be denied, it is likely that the agent reduced lipid at least in the cap and the cap became thick due to increased collagen fibers or extracellar matrix. Non-glistening yellow plaques were also changed into light yellow or white, namely vulnerability score was reduced in the treated group. All these facts suggest that Since angioscopy is an interventional and rather subjective diagnostic tool, other non-interventional and more objective tools, including measurement of plasma factors which selectively reflect vulnerability and also non-interventional therapeutic means should be developed in future to minimize the great burden of human beings, acute coronary syndromes.
